About
Reveal-Dx is a Seattle-based software company dedicated to improving lung cancer outcomes through innovative diagnostic technology. Founded in early 2021, the company leverages patented algorithms and assets from Mindshare Medical, which focused on developing AI-enabled tools for lung cancer diagnosis. The main product, RevealAI-Lung, is an AI-powered diagnostic software that evaluates the likelihood of cancer in pulmonary nodules detected on chest CT scans. It uses a proprietary malignancy scoring index to provide rapid evaluation results that integrate seamlessly into clinical workflows. This tool aims to reduce unnecessary invasive procedures, delivering results within seconds to enhance diagnostic precision and lower costs. Reveal-Dx's technology has been clinically validated, showing significant improvements in early lung cancer diagnosis and reduced false positives. The company holds various regulatory approvals, including CE Mark and Health Canada licenses, and is working towards FDA approval for use in the U.S. Reveal-Dx serves healthcare providers, including hospitals and health systems, and has established partnerships for product integration and distribution in North America.
Technologies
Keywords
Company Information
-
Employees 15
-
Founded 2014
Location
500 Yale Avenue North, Seattle, Washington, United States, 98109
